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Importance—Schizophrenia (SCZ) is a devastating psychiatric condition. Identifying the 
specific genetic variants and pathways that increase susceptibility to SCZ is critical to improve 
disease understanding and address the urgent need for new drug targets.
Objective—To identify SCZ susceptibility genes.
Design—We integrated results from a meta-analysis of 18 genome-wide association studies 
(GWAS) involving 1 085 772 single-nucleotide polymorphisms (SNPs) and 6 databases that 
showed significant informativeness for SCZ. The 9380 most promising SNPs were then 
specifically genotyped in an independent family-based replication study that, after quality control, 
consisted of 8107 SNPs.
Setting—Linkage meta-analysis, brain transcriptome meta-analysis, candidate gene database, 
OMIM, relevant mouse studies, and expression quantitative trait locus databases.
Patients—We included 11 185 cases and 10 768 control subjects from 6 databases and, after 
quality control 6298 individuals (including 3286 cases) from 1811 nuclear families.
Main Outcomes and Measures—Case-control status for SCZ.
Results—Replication results showed a highly significant enrichment of SNPs with small P 
values. Of the SNPs with replication values of P<.01, the proportion of SNPs that had the same 
direction of effects as in the GWAS meta-analysis was 89% in the combined ancestry group (sign 
test, P<2.20×10−16) and 93% in subjects of European ancestry only (P<2.20×10−16). Our results 
supported the major histocompatibility complex region showing a 3.7-fold overall enrichment of 
replication values of P<.01 in subjects from European ancestry. We replicated SNPs in TCF4 
(P=2.53×10−10) and NOTCH4 (P=3.16×10−7) that are among the most robust SCZ findings. More 
novel findings included POM121L2 (P=3.51×10−7), AS3MT (P=9.01×10−7), CNNM2 
(P=6.07×10−7), and NT5C2 (P=4.09×10−7). To explore the many small effects, we performed 
pathway analyses. The most significant pathways involved neuronal function (axonal guidance, 
neuronal systems, and L1 cell adhesion molecule interaction) and the immune system (antigen 
processing, cell adhesion molecules relevant to T cells, and translocation to immunological 
synapse).
Conclusions and Relevance—We replicated novel SCZ disease genes and pathogenic 
pathways. Better understanding the molecular and biological mechanisms involved with 
schizophrenia may improve disease management and may identify new drug targets.
Schizophrenia (SCZ) is a major public health problem1 that ranks ninth in the global burden 
of illness.2 Of a large set of prenatal and antenatal risk factors, having a first-degree relative 
with SCZ is one of the most important,3 and genetic factors account for most of this familial 
risk.4 Identifying the specific genetic variants that increase susceptibility is crucial to 
improve our understanding of SCZ and has the potential to address the urgent need for new 
drug targets.5
Although SCZ genetics have proven difficult, recent genome-wide association studies 
(GWASs) mega- and meta-analyses have suggested several promising loci.6,7 Our aim was 
to perform a comprehensive family-based replication study of promising SCZ loci. Because 
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the results from the recent mega-analysis of the Psychiatric GWAS Consortium were not 
available at the time we started the present study,6 we first conducted a meta-analysis of 18 
SCZ GWASs that included 21 953 subjects of European ancestry. The samples used for this 
meta-analysis overlapped for almost 90% with the Psychiatric GWAS Consortium study. In 
addition to selecting for replication the SNPs with the best P values in the GWAS meta-
analysis, we selected the best SNPs after integrating existing informative SCZ data sources 
with the meta-analysis results. Such a convergent functional genomic approach can improve 
statistical power to detect biologically more meaningful and reproducible effects.8 In total, 
we selected 9381 SNPs for genotyping in an independent sample of 6298 subjects, including 
3286 cases, from 1811 nuclear families. The use of nuclear families is a critical feature 
because almost all GWAS studies to date involved case-control samples, and their findings 
have been criticized as being possible population stratification artifacts.9 Because our 
family-based replication study is robust against such false-positive findings, it provides an 
unprecedented opportunity to shed more light on recent GWAS findings.
METHODS
GWAS META-ANALYSIS
Our SCZ GWAS meta-analysis involved 18 studies. After stringent quality control, 1 085 
772 genotyped and imputed SNPs were available for 21 953 subjects of European descent 
(11 185 cases and 10 768 controls). To account for possible population stratification within 
each of the GWASs, we included the first 3 principal components from the EigenSoft 
package (Helix Systems)10 plus any additional components that predicted case-control status 
(P≤.05). Additional details about the study samples and the methods can be found in 
eMethods 1, eTable 1, and eFigures 1 through 6 (http://www.jamapsych.com).
SNP SELECTION FOR REPLICATION STUDIES
Single-nucleotide polymorphisms were selected for a variety of reasons (eFigure 3 and 
eTable 2), including having the best P values in the meta-analysis and after data integration 
using Mathematically based Integration of Heterogeneous Data (MIND)11 (validation 
studies are listed in the eMethods 2). MIND estimates the (posterior) probability that an SNP 
is associated with the disease after taking all data (GWAS meta-analysis and external data 
sets) into account. It empirically “weighs” other data according to the strength of its disease-
relevant information. We used the following databases that contained significant SCZ 
information: SzGene12 database, summarizing the results of 1617 studies reporting on 952 
SZC candidate genes (excluding findings from the GWAS used in our meta-analysis); top 
regions from a meta-analysis of 32 independent genome-wide linkage scans of 3255 
pedigrees with 7413 SCZ cases13; a gene expression meta-analysis of 12 controlled studies 
across 6 different microarray platforms using postmortem brain tissue from SCZ cases and 
controls14; the OMIM database of disease genes; human orthologs of mouse genes 
associated with behavioral phenotypes relevant to neuropsychiatric outcomes15; and SNPs 
strongly associated with variation in transcript abundance in the cortex (http://
eqtl.uchicago.edu). A total of 8107 of the 9380 selected SNPs were successfully genotyped 
with the Illumina iSelect assay (http://www.illumina.com/products/
infinium_iselect_custom_genotyping_beadchips.ilmn), with a call rate of 99.94%.
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Approximately 89% of the replication samples were families from the National Institute of 
Mental Health repository, and the remaining 11% were collected by one of us (L.E.D.). 
None of these samples was used in the prior analyses, so this replication effort was 
completely independent. Each family included at least 1 subject with a DSM-III-R diagnosis 
of SCZ. After quality control, 6298 individuals (3286 cases) from 1811 families remained.
For the analyses, we first subdivided subjects into ancestral groups based on identity-by-
state sharing, as estimated using the genotyped SNPs in parents or, if they had not undergone 
genotyping, 1 randomly selected sibling per family. Three well-distinguished clusters, where 
the major self-reported ethnicity in each group was African (1262 individuals from 438 
families), European (2740 individuals from 794 families), and Asian (2296 individuals from 
579 families) ancestry, are shown in eFigure 7. Next, we used UNPHASED software,16 
which is robust to population structure when the data are complete and has only minor loss 
of robustness when data are missing. To further minimize the risk of population stratification 
effects, we first performed the analyses within each ancestral group and then combined the 3 
test statistics to obtain an overall replication P value. We limited the association testing to 
markers with a minor allele frequency of greater than 0.05 within each group. We preserved 
the direction of effects (ie, sign) so that an allele being overtransmitted in one group and 
undertransmitted in another would have no effect in this combined analysis (eMethods 2). 
Additional details are given in eTable 2 and eFigure 8.
PATHWAY ANALYSIS
To test whether multiple susceptibility alleles with small effects were organized into 
pathways, we used Consensus-PathDB, a human-centric meta-database of functional 
biological data compiled from 30 separate public sources of biological interactions.17–19 A 
list of 265 genes overlapping or flanking (±25 kilobases [kb]) the SCZ-associated SNPs with 
P<.05 in our analysis were included in these analysis. To account for multiple testing, we 
controlled the false discovery rate20 at the 0.01 level (eMethods 2 and eTable 3).
In MIND, sources of prior information used to select SNPs through data integration will 
only affect results to the extent that they contain disease-relevant information (ie, to the 
extent that genes with good P values in the sources of prior information also have good P 
values in the meta-analysis) (eMethods 3). Because most of the databases we used pertain to 
genes, bias in terms of selecting SNPs in genes as opposed to intergenic regions is expected. 
However, the selection was entirely based on the empirical support for SNPs in those genes. 
Furthermore, the pathway analyses were performed using the replication results. Therefore, 
our pathway findings are unlikely to reflect prior notions about SCZ-relevant pathways for 
which there is no empirical support (eFigure 9).
RESULTS
Figure 1 shows histograms of the P values from the association tests. Under the null 
hypothesis assuming no replication, the histograms would have had equal heights. The 
skewed histograms therefore indicated considerable enrichment of small P values. To 
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quantify this enrichment, we divided the observed median test statistic value by the expected 
median under the null hypothesis. This index, which has an expected value of 1.00 if SNPs 
do not replicate, equaled 1.19, 1.12, and 1.07 for subjects from European, Asian, and 
African ancestry, respectively, and was 1.15 for the (signed) combined analysis that required 
the same direction of effects in all 3 groups. Next, we tested whether this enrichment for 
small P values was statistically significant (eMethods 3). Owing to the large number of 
SNPs, large sample size, and family-based association tests allowing for missing genotypes, 
it was computationally not feasible to perform a sufficiently large number of permutations to 
obtain empirical P values. Instead, we obtained the lower and upper bounds assuming no 
linkage disequilibrium (LD) and very high LD, respectively, among the SNPs. When we 
assumed no LD, the P value was so small that the statistical test in the R package returned a 
0; when we assumed an extremely high LD between the SNPs, we obtained P=2.0×10−4. 
Thus, even in the most conservative scenario, the test indicated significant enrichment of 
small P values in the replication. We also performed sign tests that examined whether the 
direction of effects was similar in the GWAS meta-analysis and the replication study. Of the 
SNPs with replication values of P<.01, the proportion of SNPs that had the same direction of 
effect of 89% (P=2.20×10−16; 95% CI, 82%–94%) for the combined ancestry group and 
93% (P=2.20 10−16; 95% CI, 88%–97%) for European subjects. Again, in both cases the 
statistical test in the R package returned a 0, indicating that this pattern was almost 
impossible to occur by change. The mean odds ratios of these SNPs were 1.2 and 1.3 in the 
combined and European study samples, respectively. Overall, our findings confirm the 
polygenetic nature of SCZ and show that we replicated a substantial number of susceptibility 
alleles with small effects.7,21,22
We anticipated that SNPs replicate better in the same ancestral group in which they showed 
their initial association signals. The GWAS meta-analysis was the main source of SNP 
selection and involved European subjects only, which likely explains why SNPs replicated 
relatively better in the European group. Although non–major histocompatibility complex 
(MHC) SNPs replicated in all ancestral groups, the SNPs in the MHC region did not: we 
observed a large 3.7-fold enrichment of values of P<.01 in European samples, but findings 
dissipated in non-European samples. This pattern seems consistent with the exceptionally 
large LD differences across ancestral groups in this region resulting from its evolutionary 
significance (eg, it harbors many genes affecting the immune response).
For SNPs that do not have effects, we would not expect to see any difference between 
markers selected with or without data integration in the replication study. To compare the 2 
approaches, we therefore first selected all SNPs with P values of less than .01 to enrich for 
markers with effects. Figure 2 shows that SNPs selected through data integration replicated 
as well as SNPs selected on the basis of having the top-ranked P values in the meta-analysis 
without data integration. Some of the SNPs selected through data integration even had P 
values with ranks as high as 25 000 in the meta-analysis. The fact that such SNPs would not 
have been selected on the basis of their P value but do replicate demonstrates the value of 
considering existing data sources.
We applied a stringent definition of replication requiring the same SNP to have the same 
direction of effect in the replication study and meta-analysis. Table 1 (combined analysis) 
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and Table 2 (European analysis) report the SNPs that replicated at P≤.005. The P values for 
all SNPs can be downloaded from http://www.people.vcu.edu/~ejvandenoord/. Compared 
with the meta-analysis or when combining P values from the 3 ancestral groups, sample size 
was ignored when calculating the overall P value across the replication study and meta-
analysis. In the GWAS meta-analysis, the effect sizes will be overestimated and P values will 
be too optimistic owing to the winner’s curse.23–25 Furthermore, because the sample size 
was much larger in the meta-analysis, these P values would have dominated the combined P 
value. Ignoring samples sizes avoids overly optimistic P values while still providing some 
quantification for the combined evidence of a specific SNP across the meta- analysis and 
replication study. Some SNPs in Table 1 showed substantial allele frequency differences 
across ancestral groups. However, in addition to using nuclear families, the UNPHASED 
analyses were performed within each ancestral group to provide a second layer of protection 
against possible stratification effects.
Table 3 shows the results from the pathway analyses. Where the same gene combination 
from our input list indicated multiple pathways, we show only the most significant instance 
to eliminate redundancy. Fourteen pathways were significant at a false discovery rate of 
0.01. The 3 most significant pathways were axon guidance (P = 5.26×10−6), developmental 
biology (P = 1.29×10−5), and neuronal systems (P = 1.37×10−5). Larger pathways, such as 
these 3 top findings, which each include more than 250 genes, frequently incorporate several 
more specific themes, and this can be further observed in Table 3. For example, axon 
guidance includes the smaller L1 cell adhesion molecule (L1CAM) pathway interaction (P = 
6.75×10−5), which was also significant in our analysis.
COMMENT
In our study we replicated SNPs in TCF4 (P = 2.53×10−10 in the European analysis) and 
NOTCH4 (P = 3.16×10−7 in the combined and P = 5.22×10−7 in the European analyses) that 
are among the top 10 most promising SCZ candidate genes.12 Other loci previously showing 
association with SCZ include GRIK326 (P = 3.48×10−7) and BRD127 (P = 1.53×10−7) in the 
combined analyses and FEZ128 (P = 3.21×10−6) in the European analysis. In the combined 
analyses, we replicated (P = 2.90×10−7) SNPs in an approximately 230-kb region on 
chromosome 10q24, which was recently reported to be associated in part with SCZ.6 This 
region encompasses an uncharacterized open reading frame (C10orf32) as well as AS3MT, 
CNNM2, and NT5C2. AS3MT may play a role in arsenic metabolism.29 CNNM2 is 
abundantly expressed in brain and functions as a divalent metal ion transporter,30 whereas 
NT5C2 hydrolyzes purine nucleotides and is involved in maintaining cellular nucleotide 
balance.31 A notable novel finding in the combined analysis (P = 1.69×10−5) is BCL2, 
which has been suggested as a marker for neuronal differentiation.32 Lower levels of BCL2 
have been observed in the temporal cortex of patients with SCZ compared with controls.33
After TCF4, the second most significant finding (P = 3.51×10−7) in the European replication 
involved POM121L2, a gene with unknown function but in a location that has previously 
been associated with SCZ.7 In addition to NOTCH4 and POM121L2, several other genes in 
the MHC region replicated. The LD between the MHC SNPs reported in Table 2 (eFigure 8) 
showed a complex pattern and ranged from 0 to high LD (eg, SNPs in NFKBIL1, PRRC2A, 
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and BAG6). Many of these genes are involved in immune response, although recent 
evidence suggests a possible role in neuronal signaling and activity-dependent changes in 
synaptic connectivity.34 This finding was true for some SNPs outside the MHC as well. For 
example, several genes with significant findings on chromosome 19 (eg, CLC) code for 
proteins that belong to the galectin family, which regulates immune response.
In the pathway analysis, 43 SCZ-associated genes were included in the 14 most significant 
pathways. Many of these are related to neuronal function and the immune system, 2 
functions of potential relevance for SCZ, which are discussed in this section. The most 
significant pathway finding, axon guidance, includes genes involved in the process by which 
neurons send out axons to reach the correct targets. Growing axons sense guidance cues in 
the environment and respond by undergoing cytoskeletal changes that determine the 
direction of axon growth. Several highly conserved families of axon guidance molecules and 
their receptors have been identified.35 Among the SCZ-associated genes in our study that are 
part of this pathway are ROBO2 (roundabout, axon guidance receptor, homologue 2), which 
is a receptor for the axon guidance molecule SLIT2. The related gene SLIT3 is also among 
our findings. As mentioned already, L1CAM interactions is a subpathway of “axon 
guidance” that was also significantly enriched for SCZ-associated genes. The L1CAM 
family includes 4 structurally related proteins36 of which neurofascin (NFASC) is among 
our SCZ-associated genes that overlap with the L1CAM interaction reference pathway. 
Neurofascin has been shown to participate in neurite outgrowth and stabilization of neuronal 
structures, the latter particularly through interaction with ankyrins.37 This interaction was 
also observed in our pathway analysis (interaction between L1 and ankyrins, P = 2.78×105). 
Ankyrin 1, 2, and 3 (ANK1, ANK2, and ANK3) are part of our SCZ-associated genes. 
Ankyrins are adaptor proteins that couple membrane proteins, such as voltage-gated sodium 
channels, to the developing cytoskeleton.38 The observed theme of cell adhesion molecules 
from the KEGG (Kyoto Encyclopedia of Genes and Genomes) database (P = 5.97×10−4) 
replicates a previous pathway analysis of large-scale SCZ genetic studies, even to the point 
that we observe many of the same specific genes, including CNTNAP2 and NRXN2.39
The generic neuronal system pathway in the Reactome database consists of several 
subpathways, such as transmission across chemical synapses, which was also among our 
highly significant findings. Thus, in addition to the pathways involved in neuronal growth 
and projection mentioned in the previous paragraphs, we observe associations with chemical 
neurotransmission. Among the genes in this pathway are several nicotinic acetylcholine 
receptors (CHRNA5, CHRNA2, and CHRNA3) that are also significant in their own 
subpathway (P = 2.21×10−4); voltage-gated calcium channels, such as CACNB2 and 
CACNB4, γ-aminobutyric acid B2 receptor (GABBR2); and a glutamate transporter 
(SLC1A3). Calcium signaling in particular has previously been identified as a core theme in 
the etiology of SCZ through large-scale genetic studies. Additional notable genes present in 
the transmission across chemical synapses pathway include the cyclic adenosine 
monophosphate response element binding protein 1 (CREB1) and the N-ethylmaleimide–
sensitive factor (NSF). CREB1 is a transcription factor involved in mediating gene 
regulation after signaling events,40 whereas NSF is involved in vesicle trafficking and 
membrane fusion.41
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A final, relevant theme among the significant pathways is the immune system. Antigen 
processing and presentation pathways from the KEGG and Biocarta databases were 
significantly enriched for SCZ-associated genes. Although the composition of these 
pathways was somewhat different between the 2 databases, the core genes of TAP1, TAP2 
and HLA-DRA were common to both. The transporter associated with antigen processing 
(ie, TAP) is composed of a heterodimeric complex of TAP1 and TAP2. It is a key element in 
the immune recognition of cells compromised by virus infection or malignant 
transformation. The transporter is crucial in MHC class I antigen presentation by 
translocating proteasomal degradation products into the lumen of the endoplasmic reticulum 
for loading onto MHC class I molecules.42 An additional pathway related to the immune 
system, translocation of ZAP-70 kinase to the immunological synapse, was also significant. 
The zeta chain–associated protein kinase 70-kDa (ZAP-70) is an integral part of the adaptive 
immune system because it initiates signaling at the immunological synapse between a T cell 
and an antigen-presenting cell.43 Previous large-scale genetic studies have implicated the 
MHC region on chromosome 6,44 and most of the genes that we observe in the present study 
to be involved in these immune system–related pathways, such as the TAP and HLA genes, 
map to the MHC region. Therefore, the evidence that ties the MHC region, and by 
implication the immune system, to the etiology of SCZ is increasing.
CONCLUSIONS
We integrated results from a meta-analysis of 18 SCZ GWASs with existing informative 
SCZ databases to select SNPs for a family-based replication study. Results suggested a 
considerable enrichment of small P values in the replication study. Test results showed that 
this enrichment was statistically significant. Furthermore, of the SNPs with replication 
values of P<.01, the proportion of SNPs that had the same direction of effect as in the 
GWAS meta-analysis was about 90%, which is almost impossible to occur by chance. 
Finally, analyses suggested several significant pathways, which again suggested that SNPs 
replicated. Because the group of selected SNPs replicated as a whole, it follows that 
individual SNPs in the replication study replicate. A complication was that rather than a few 
SNPs having large effects, many SNPs appeared to have small effects. Although our 
pathway analyses of these SNPs implicated specific pathogenic processes, some caution is 
required before making strong statements about the replication status of individual SNPs. 
Other studies have reached a similar conclusion that for SCZ, many SNPs with small effects 
may be involved and these SNPs replicate as a group.21,45 Our article adds to these studies. 
The facts that we used a family-based replication (thereby minimizing the probability that 
population substructure accounts for the replication) and tested a much smaller set of SNPs 
pinpoints more precisely the genes that are likely involved.
Some of the SNPs selected through data integration had ranks up to 25 000 in the meta-
analysis. Although these SNPs would never have been selected on the basis of their P value, 
they replicated as well as SNPs selected on the basis of having the top-ranked P values in the 
meta-analysis without data integration. This demonstrates the value of considering existing 
data sources. This conclusion also emerges from a study by Ayalew et al,46 who identified 
and prioritized genes involved in SCZ by gene-level integration of GWAS data with other 
genetic and gene expression studies. Some of the top findings in their study were the 
Aberg et al. Page 8













previously reported SCZ candidate gene TCF4 and the pathways involved in synaptic 
connectivity and glutamate signaling. Following the same concept but using a more 
statistical approach, we also identified SNPs in TCF4 and identified pathways related to 
cellular connectivity and signaling. Given that the number of (publicly) available databases 
and the tools to curate these data are increasing rapidly, future studies should be able to 
capitalize even more on data integration.
In addition to SNPs in two of the most promising SCZ candidate genes, we replicated 
several recently identified susceptibility genes for SCZ in an independent family-based 
replication sample. Our family-based replication also suggests that previous claims 
implicating the MHC region as a susceptibility region for SCZ cannot be discarded as 
population stratification artifacts. Pathway analyses of the many small effects reveal several 
biological themes involved in brain function, immune response, and biological functions of 
potential importance for the development of SCZ. The present investigation is, to our 
knowledge, the first family-based replication that confirms several of the recent mega- and 
meta-analyses top findings in a completely independent study sample using a different 
genotyping assay than what was used in the initial detection.
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Histograms of P values from the family-based association analyses. Results are given in 
subjects from European (A and E), Asian (B and F), and African (C and G) ancestry. The 
combined analyses (D and I) present results from the test statistics across the 3 groups while 
taking the direction of effects into account. Plots are given for single-nucleotide 
polymorphisms not including (A–D) and including (F–I) the major histocompatibility 
complex region.
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Comparison of single-nucleotide polymorphisms selected through data integration (blue), 
that have a top genome-wide association study (GWAS) meta-analysis P value (red), or both 
(green). P values in the family-based replication study are calculated on a −log10 scale.
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